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1. Introduction
In 2012, rectal cancer affected 40,290 Americans. Colon and rectal cancer resulted in a mortality
of 51,690 individuals during the same year [1]. Patients affected with rectal cancer who have
a clinical stage II (T3-T4, NO, MO) or III (Any T, N1-N3, M0) tumor are treated with pre-
operative chemoradiation (CRT) followed by surgical intervention 5-10 weeks after the last
CRT treatment. An adequate oncologic operation involves removal of the tumor and the entire
mesorectum (total mesorectal excision). This has been demonstrated to decrease local recur‐
rence substantially as the lymphatic drainage of the rectum is contained within the investing
fascia (mesorectum). Distal rectal tumors involving the anorectal sphincter complex are
classically treated with an abdominoperineal resection (APR); whereas, more proximal tumors
might be treated with an anterior protosigmoidectomy with a primary colorectal anastomosis
(LAR). There has been a substantial shift in the number of APR operations to LAR procedures
over the past decade owing to the implementation of new circular stapling devices and the use
of neoadjuvant CRT.
2. The rectum
In a Cochrane review of 19 clinical trials assessing preoperative radiotherapy vs. surgery alone,
the rectum was alternatively defined as below the sacral promontory in three studies, below
the pelvic brim in one study, and by the distance from the anal verge in several studies: 12 cm
(one study), 13 cm (one study), 14 cm (one study), 15 cm (five studies), and 16 cm (one study)
[2]. The hazard ratio for recurrence in patients receiving radiotherapy was less if tumors were
located within five to 10 cm from the anal verge, but there was no difference in local recurrence
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in patients treated with combination radiotherapy and surgery vs. surgery alone in patients
that had tumors 10.1 cm from the anal verge [3]. Thus, the benefit of radiotherapy appears to
be for more distal tumors (0-10 cm from the anal verge). For the purpose of selecting patient
to receive pre-operative CRT, practice guide lines in the United States by the National Cancer
Institute (NCI) [4]and the National Comprehensive Cancer Network (NCCN) [5] have defined
the rectum to be 12 cm from the anal verge.
3. Indications for neoadjuvant chemoradiation
The addition of preoperative radiation therapy to TME decreases locoregional recurrence from
approximately 8% to 2%. The combination of chemotherapy and radiation (CRT) further
decreases local recurrence. Chemotherapy also increases the number of patients which achieve
a pathologic complete response (pCR), i.e. no detectable tumor after resection. This modality
also reduces tumor burden in some patients and might allow a sphincter preserving operation
(i.e. LAR) as opposed to an APR, allowing a patient to avoid a permanent colostomy. The rate
of pCR is approximately 25% [6;7]. Patients who achieve pCR have better long-term outcomes
compared to patients who only have a partial response or no response at all [8]. Current guide
lines in the United States [4;5] dictate that patients with stage II (T3-T4) or stage III (any T with
positive regional lymph nodes) should be treated with neoadjuvant CRT. Patients with stage
I (T1-T2) disease or those with distant metastases (stage IV) generally do not receive neoad‐
juvant CRT. However, in instances of synchronous liver metastases for which liver resection
is planned, neoadjuvant radiation may be considered. These recommendations emanate from
the low rate of recurrence (4%) in patients with stage I tumors treated with surgery alone [9].
Further, there is no difference in the rate of locoregional recurrence in patients with stage IV
tumors treated with radiotherapy and surgery compared to palliative surgery alone [3].
Similarly, there is no difference in outcomes in patients with distant metastases treated with
neoadjuvant radiotherapy and surgery vs. palliative surgery alone [3]. Thus, the standard care
of practice is to provide neoadjuvant CRT in patients with stage II and III rectal tumors.
4. Clinical staging of rectal cancer
Staging of rectal cancer begins with a thorough history and physical examination. The most
common symptom of rectal cancer is bright red blood per rectum. Physical examination of the
abdomen is important to identify any evidence of liver disease (ascites) or masses. A lymph
node examination is important in any patient suspected of having cancer. Rectal examination
will reveal distal tumors and is mandatory in the evaluation of patients with colorectal cancers.
In such cases information regarding the size, degree of fixation, distance from the anal
sphincters is important. In women, a rectovaginal examination may reveal extent of disease.
A full colonoscopy is indicated to identify synchronous lesions (present in approximately 5%
of cases). Rigid proctoscopy will define the distance of the lesion from the anus and can be
critical in cases where the distance from the anus is not clear.
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Because only stage II and III tumors are treated with pre-operative CRT, clinical staging is
pivotal in guiding treatment options. There are currently two modalities to assess tumor stage
(T stage) in the pre-operative setting: (1) endorectal ultrasound (EUS) and (2) Magnetic
Resonance Imaging (MRI). The efficacy of these modalities has been assessed by two meta-
analyses [10;11]. One study favors EUS [10] and the other MRI [11]. In the first analysis, 90
studies were included and assessed the accuracy of EUS, MRI, and CT in pre-operatively
staging rectal cancer. The results demonstrated that EUS and MRI were similar in terms of
sensitivity (Sn) with regards to tumor depth into the muscularis propia (94%). EUS was
superior in determining muscularis propia invasion [specificity (Sp) of 86%] compared to MRI
(Sp = 69%) and was an overall sensitive strategy (Sn = 90%) for perirectal tumor invasion
compared to MRI (Sn = 82%) [10]. A second meta-analysis interrogated 84 studies. This study
showed no difference in these modalities in evaluating the nodes (N-staging) [11]. In seven
studies, MRI was a superior strategy in evaluating involved circumferential margins [11]. MRI
seems to be emerging as a preferred modality for the assessment of rectal cancer staging in the
pre-operative setting. However, the use of either of these modalities is largely based on
institutional experience. The sensitivity of EUS following CRT is less compared to virgin tissue.
Thus, MRI may be a preferred modality to determine response to neoadjuvant CRT.
5. Neoadjuvant chemoradiotherapy
The management of stage II and stage III rectal cancer is a tri-modality approach (Radiother‐
apy, Chemotherapy and Surgery) and patients are best managed following discussion at a
multidisciplinary conference.
5.1. Radiotherapy
Initial studies evaluated the efficacy of radiotherapy without pre-operative chemotherapy. The
data has been summarized in two meta-analyses addressing the benefit of preoperative
radiation [12;13]. While the data on overall survival was not clear in these analyses, there was
a clear decrease in the rate of local recurrence (46% in patients receiving preoperative radiation
vs. 53% in the control group). These data established the benefits of preoperative radiotherapy
followed by surgery.
5.1.1. Short course vs. long course radiotherapy
In Europe, small fractions of ionizing radiation 5.0 Grey (Gy) X 5.0 (over five days), for a total
of 25.0 Gy without chemotherapy, are employed. With this strategy, the Swedish Rectal Cancer
Trial found an improved rate of survival at five years with preoperative radiation [14]. In the
United States, the typical IR dose is 45.0 to 50.4 Gy given in small doses (1.8 Gy/day) for five
to six weeks [5]. In contrast to short course radiotherapy, in the United States, long course
radiotherapy is given in combination with neoadjuvant chemotherapy. The interval between
completion of radiation and subsequent operation is an area of some debate (see below) but
is typically 5-10 weeks.




Preoperative chemotherapy is generally used as a radiosensitizer. The EORTC group demon‐
strated that the addition of chemotherapy (5-FU) to the use of preoperative radiation reduced
the risk of local recurrence by approximately 50%, from 17.1% to 8.7%. There was not a
significant difference in overall survival in this study. Other trials have shown similar
improvements in local control. Based on this data, the most established agent used in the pre-
operative setting in combination with radiation has been 5-fluorouracil (5-FU). The oral form
of 5-FU (Capecitabine) is also being widely used in place of 5-FU with similar results [15].
Several chemotherapeutic agents used for the management of colon cancer in the adjuvant
setting and for patients with metastases have been evaluated as possible radiosensitizers.
These agents include: irinotecan [16], oxaliplatin [17], bevacizumab [18] and cetuximab [18].
With such strategies, there is still a wide response to ionizing radiation and these agents are
not in widespread use at this time.
5.3. Pathologic complete response
A pathologic complete response (pCR) occurs in patients who undergo resection of the rectum
and no residual tumor is identified. Patients who have a pCR demonstrate superior survival
than those without. The EORTC 22921 showed an increased rate of pCR in patients who
underwent chemoradiotherapy (13.7%) compared to patients who received radiation therapy
alone (5.3%). A European trial inclusive of 762 patients receiving preoperative chemoradiation
compared to radiation alone, the pCR rate was 11.4% vs. 3.6%, respectively [19]. A recent
randomized phase II trial assessing combined chemoradiation for rectal cancer showed 28%
of patients achieved a pCR. Further, 78% of patients exhibited tumor down staging [20]. Thus,
chemotherapy has an additive effect to radiotherapy and has become the standard of care for
patient with stage II/III tumors within 12 cm of the anal verge [5].
In the United States current guidelines recommend pre-operative radiation [50.4 Gy] in 25-28
fractions combination with 5-FU infusional or bolus with leucovorin [425 mg/m2/d] or
capecitibine [825 mg/m2]. Neoadjuvant treatment is followed by surgery five to ten weeks later.
While some investigators have shown that longer periods between neoadjuvant CRT and
surgery might be associated with an increase rate of pCR [21], this approach is still under
investigation [22].
6. Surgery
For stage II and III patients treated with CRT, surgical intervention must be planned within
five to ten weeks after the last dose of chemoradiation. Although a longer window between
neoadjuvant chemoradiation and operative intervention has been associated with higher rates
of pCR, this must be assessed in case-to-case basis [21;22].
Transabdominal operations (LAR or APR) are the operations of choice for stage II and stage
III rectal cancers. For small tumors with a good histology and for a patient with a prohibitive
risk of surgical intervention, a transanal approach might be an alternative approach.
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6.1. Transabdominal operations
Two operations are typically performed for rectal cancer. The abdominoperineal resection
involves the removal of the distal rectum and perineum with clear tumor radial margins
laterally to the pelvic sidewalls. Thus, part of this operation is the creation of a permanent
colostomy. A low anterior resection involves the removal of the tumor and the creation of an
anastomosis. This might require a temporary loop ileostomy especially in patients that have
received neoadjuvant chemoradiation.
6.1.1. Abdominioperineal Resection (APR)
An abdominoperineal resection (Figure 1) necessitates a permanent colostomy, which
frequently carries negative perception as a drastic change in quality of life for patients.
Although a permanent stoma does necessitate some changes for patients, data is emerging that
quality of life following an APR is not significantly less than that following an LAR [23]. This
is related to the relatively high rate of complications following LAR, including sexual dys‐
function, pain and fecal incontinence. However, an APR is associated with a high rate of
perineal wound infections [24]. Furthermore, obtaining clear radial margins is more difficult
with an APR compared to an LAR [23;25]. As a result, there is an oncologic advantage in
peforming an LAR compared to an APR [25]. Thus, in patients with preserved rectal tone, the
operation of choice, is an LAR provided tumor associated factors make this possible.
Figure 1. Abdominoperineal Resection (APR). The rectal tumor
Figure 1. Abdominoperineal Resection (APR). The rectal tumor is removed, a permanent colostomy is created and the
anus is obliterated.
6.1.2. Low Anterior Resection (LAR): Total Mesorectal Excision (TME)
An LAR (Figure 2) involves the creation of a primary anastomosis. The area confined within
the investing fascia of the rectum and the presacral fascia involves the vascular and lymphatic
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structures of the mid-rectum. An en bloc resection of the rectum that circumscribes these
structures is termed a TME (Figure 3). Superiorly, the mesorectum is defined at the level of
the sacral promontory or the division of the right and left superior hemorrhoideal arteries.
The mesorectum extends distally and reduces posteriorly at the level of the investing fasica
of the levators (Waldeyer's Fascia). Prior to in the introduction of TME the rate of recur‐
rence for rectal cancer was 25.0%. This rate has been reduced to 5.0% following the introduc‐
tion of the TME [26].
Figure 2. Low Anterior Resection (LAR). The
Figure 2. Low Anterior Resection (LAR). The rectum involving the tumor is resected and a primary anastomosis is cre‐
ated with a circular stapling device.
6.1.3. Proximal margin of resection and level of arterial ligation
No studies have interrogated the length required for proximal resection. Because of the
continuity with the colon this is not such a concern. NCI guidelines recommend a 5-cm segment
Tumor
Figure 3. Total Mesorectal Excision (TIME). The dotted line represents the line of resection. The tumor is resected and
a primary anastomosis is performed
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of resection proximal to the tumor [4]. While the inferior mesenteric artery (high ligation) was
typically the level of arterial ligation recommended, this practice was associated with a
decrease in innervation and perfusion to the anastomosis. The evidence demonstrating that
this has a superior oncologic compared to ligation at the level of the superior rectal artery (low
ligation) is lacking. Thus, low ligation has become the preferred strategy [27] (Figure 4).
6.2. Laparoscopic surgery for the management of adenocarcinoma of the rectum
Minimally invasive surgery has made laparoscopic resection of rectal cancer possible. How‐
ever, at this juncture, this procedure remains investigational for the management of rectal
cancer [5]. It is currently, recommended to include patients in study protocol to continue to
address the benefits of the laparoscopic approach in rectal cancer including: oncologic efficacy,
complication rates, conversion rates, patient benefit, and cost-effectiveness.
Short term outcomes have not been different in patients treated with the laparoscopic approach
compared to the open techniques [28]. Multiple case series reporting laparoscopic TME have
documented technical feasibility with satisfactory short term outcomes [29]. While case reports
have also reported the ability of a robotic proctectomy [30], these studies need to be replicated
in large series compared to the “gold-standard” to determine the general applicability of
innovative approaches.
In contrast to colon cancer, where laparoscopy has been compared to the open approach
[31-33], for rectal cancer these studies are currently needed. The Conventional Versus Lapa‐
roscopic-Assisted Surgery in Colorectal Cancer (CLASICC) trial specifically addressed rectal
cancer [32]. In this study, the rate of complications was similar. However, the rate of positive
CRM was twice in the laparoscopic approach compared to the open technique (12% vs. 6%;
p=0.19). While this was only a trend and not correlated with an increase in the rate of recur‐
rence, these findings need to be further investigated. Additionally, there was also a trend




Figure 4. High ligation occurs at the root of the IMA (A). Low ligation occurs at the level of the superior rectal ar‐
tery (B).
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A randomized controlled trial [34] and institutional case series [35;36] indicate that the
laparoscopic and the open TME have similar oncologic outcomes. More data on the long term
outcomes of the laparoscopic approach will be shed with further analysis of the Colon Cancer
Laparoscopic or Open Resection (COLOR) II [37] and the and the American College of
Surgeons Oncology Group trial Z6051 is completed.
Thus, the current data suggest that the short-term outcomes of laparoscopic and open surgery
are similar. It is crucial to analyze the current data of the available studies carefully as patient
selection and the experience of the institution/surgeon are paramount in the current available
literature. Long term data regarding oncologic outcome and functional status remain at large,
as do data demonstrating patient benefit and cost effectiveness [38].
6.3. Transanal excision
An alternative treatment for early stage rectal cancers is a transanal excision. Candidates for
this approach have small (≤ 3-cm) stage I (T1) tumors located within 8-cm from the anal verge
that occupy less than 30% of the circumference of the bowel with good histological features is
a transanal removal of the tumor with clear margins. There is a substantial risk for local
recurrence with this approach. Local rates of recurrence with the transanal approach vs.
similarly staged tumors treated with a transabdominal approach is 13.2% vs. 2.7%; respectively
[39]. Twenty percent of patients with T1 tumors who undergo radical resection are discovered
to have lymph node metastases [39]. Patients with rectal cancer treated exclusively by local
resection show a rate of local recurrence of 9.7% for T1, 25% for T2, and 38% for T3 cancers [40].
In patients that received systemic chemotherapy after the transanal excision, the local recur‐
rence rate was substantially decreased to: 9.5% for T1, 13.6% for T2, and 13.8% for T3 cancers
[40]. This approach is, perhaps, of most benefit in patients with a high operative risk.
7. Adjuvant chemotherapy
Patients with stage II/III rectal cancer should be treated with adjuvant chemotherapy as soon
as they are able. Current regimens for this approach extrapolate the experience with colon
cancer such that FOLFOX (5-FU/leucovorin, and oxaliplatin) for six months is recommended.
5-FU with or without leucovorin as well as capacitibine with or without oxaliplatin are also
alternative options for treatment in the adjuvant setting [5].
8. Pathological analysis of rectal cancer
8.1. Staging
In rectal cancer staging, the prefix “p” refers to pathological staging and “yp” indicates
pathological staging after neoadjuvant chemoradiation.
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The number of recommended nodes to be retrieved to accurately stage tumors is 12 according
to the NCCN guidelines [5]. In patients treated with neoadjuvant therapy, the number of nodes
resected during surgery is 3-6 less compared to patients treated with surgery alone [41-43].
Thus, care must be taken by the surgeon to remove all involved nodes and by pathology for a
careful analysis of the specimen.
8.2. Pathological Inspection of the tumor
8.2.1. Circumferential Resection Margin (CRM)
The circumferential margin (CRM) is important during pathological assessment of tumors in
rectal cancer [44]. The CRM refers to assessment of the non-peritonealized area (bare area) of
the rectum created by subperitoneal dissection during surgery. Tumors within 1 mm of the
resection margin are defined as having a positive CRM. Additionally discontinuous spread or
lymph node involvement within 1mm of the CRM is defined as positive. CRM is a predictor
of local recurrence in patients receiving surgery as the only modality of treatment of rectal
cancer [25;45]. Patients whose CRM is less that 2 mm have a recurrence rate of 16% compared
to 5.8% for patients having a CMR over 2mm. The rate of metastases is also higher in patients
with less than 2mm margins vs. greater that 2mm (37.6 vs. 12.7%; respectively) [26]. This
observation underscores the importance or radial margins in rectal surgery. Other studies have
shown that the CRM is an important predictor of local recurrence, distant metastasis, and
overall survival in patients receiving induction CRT compared to patients treated with surgery
alone [25]. Thus, pathological evaluation of the resected rectal tumor must include the distance
to the tumor to the closest CRM.
8.2.2. Determining response to induction chemotherapy
Pathological tumor response following neoadjuvant therapy is graded from 0 to 3. A grade of
0 indicates complete response without any viable cells; while 3 denotes minimal or no response
to treatment. It is important for the pathologist and the surgeon to note the response of CRT
after surgery to determine if the current regimens are adequate for the patient population and
also to determine the possible aggressiveness of the tumor and plan for adjuvant therapies.
9. Clinical Complete Response (cCR)
Studies continue to accumulate that document the possibility of observing patients who
achieve a clinical complete response following neoadjuvant chemoradiation [46;47]. The first
study was reported by Habr-Gama’s group in 2004 [46]. In this study, 8% of patients considered
to have recurrence had a complete pathological response following surgery. Patients with
rectal tumors within 0-7 cm from the anal verge received pre-operative radiotherapy (50.4 Gy)
and chemotherapy [5-FU (425 mg/m2/d) + folinic acid (20 mg/m2/d)]. Re-staging was per‐
formed 8 weeks after treatment and included proctoscopy with rectal biopsies. Complete
clinical response was defined by the absence of any abnormalities during proctoscopy. A rectal
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scar or a positive biopsy was defined as an incomplete response. These patients did not receive
postoperative chemotherapy unless they had recurrent disease. These findings were then
reproduced by Maas et al [47].
Maas et al compared patients that achieved a cCR to patients who had a pathological complete
response after surgery. Twenty-one subjects were included in the study arm and 20 in the
control group. The major differences in these studies include the follow up in Maas vs. Habr-
Gama’s studies (24.8 vs. 57.3 months; respectively). While radiotherapy was similar, Maas used
capecitabine rather than 5-FU. Additionally, the definition of cCR was different in these two
studies. Habr-Gama used proctoscopy and rectal biopsies while Maas relied on magnetic
resonance imaging (MRI), endorectal ultrasound, and biopsies. Finally, all pre-operatively
staged III patients received adjuvant chemotherapy consisting of oxaliplatin and capecitabine
in Maas study and none in Habr-Gama’s.
While there are some differences between the studies by Habr-Gama and Maas, they provide
an excellent platform to build on further prospective cohort studies. Further, two other smaller
studies have replicated these observations [48;49].
10. Complications
Complications from rectal surgery are typically associated with bladder and sexual dysfunc‐
tion. A TME has been associated with bladder dysfunction (17.8%), loss of erection (27.7%),
and lack of ejaculation (33.9%) [50]. Up to 30% of patients with attempted curative surgical
intervention will eventually develop regional (pelvic) recurrence [9]. Treatment failure is
largely dependent on the cohort of patients studied and combined to patients who develop
metastasis, the rate is substantially high.
11. Conclusions
The management of rectal cancer is in dynamic evolution. Drastic improvements have
occurred over the past 20 years. However, the 5-year survival for these patients remains
unacceptably high. The tri-modality approach has demonstrated clear advantages. In a small
segment of patients (~25%) the tri-modality approach might be reduced to a bimodality
treatment avoiding surgery in patients that achieve a clinical complete response. However,
this strategy should be undertaken only in the setting of an Institutional Board Review
protocol. Efforts to improve local control and survival in rectal cancer are continuing in
multiple clinical and preclinical studies. An understanding of specific molecular pathways
leading to a response in neoadjuvant modalities will refine the segment of patients who might
need an operation sooner compared to patients who might be observed. Ongoing trials on the
laparoscopic approach for rectal cancer will shed light into the benefits of this practice.
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